2016 ASH: Genetic Determinants of Response to Guadecitabine (SGI-110) in AML

/in , ,

Summary

Guadecitabine is a next generation hypomethylating drug with improved pharmacokinetics and pharmacodynamics compared to decitabine and demonstrated clinical activity in both treatment naïve (tn) and relapsed-refractory (rr) AML. Previous studies reported similar response rates to guadecitabine in different cytogenetic subsets but it remains unknown whether this extends to genetic changes.

View further details below

2016 ASH: Genetic Determinants of Response to Guadecitabine (SGI-110) in AML